Key Insights

Highlights

Success Rate

85% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

11.8%

6 terminated out of 51 trials

Success Rate

85.0%

-1.5% vs benchmark

Late-Stage Pipeline

25%

13 trials in Phase 3/4

Results Transparency

29%

10 of 34 completed with results

Key Signals

10 with results85% success

Data Visualizations

Phase Distribution

44Total
Not Applicable (3)
Early P 1 (1)
P 1 (4)
P 2 (23)
P 3 (10)
P 4 (3)

Trial Status

Completed34
Terminated6
Unknown5
Recruiting4
Not Yet Recruiting2

Trial Success Rate

85.0%

Benchmark: 86.5%

Based on 34 completed trials

Clinical Trials (51)

Showing 20 of 20 trials
NCT06746350Not ApplicableRecruitingPrimary

Feasibility of Integrating Thermotherapy for Treatment of Cutaneous Leishmaniasis in Primary Health Care Setup

NCT07506967Not ApplicableNot Yet Recruiting

Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers

NCT06798402Phase 2RecruitingPrimary

Ciprofloxacin Intralesional Injection for the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate

NCT06797544Phase 2RecruitingPrimary

Intralesional Injection of Levofloxacin for the Management of Cutaneous Leishmaniasis

NCT07149753Phase 1Not Yet RecruitingPrimary

Pilot Study: Miltefosine Gel (G-MTF) in Patients With Cutaneous Leishmaniasis

NCT06798415Phase 2RecruitingPrimary

Intralesional Injection of Metronidazole for the Management of Cutaneous Leishmaniasis

NCT06692985CompletedPrimary

Epidemiology of Cutaneous Leishmaniasis in Niger, Mali, Togo : Mapping of Clinical Cases, Species, Reservoirs and Vectors of the Disease

NCT04699383CompletedPrimary

Documentation of Patient Outcomes for SSG/Allopurinol Combination Treatment in Ethiopia

NCT01300975Phase 2Completed

Intralesional Antimony for Bolivian Cutaneous Leishmaniasis

NCT01050907Phase 2Completed

Miltefosine to Treat Mucocutaneous Leishmaniasis

NCT04340128Phase 3CompletedPrimary

Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL)

NCT03023111Phase 3CompletedPrimary

Miltefosine and GM-CSF in Cutaneous Leishmaniasis

NCT00884377Phase 2CompletedPrimary

Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis

NCT00344084CompletedPrimary

Surveillance for Leishmaniasis Skin Lesions in Mali

NCT02687971Phase 2CompletedPrimary

Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨

NCT00657917Phase 2TerminatedPrimary

Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396

NCT00471705Phase 3CompletedPrimary

Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia.

NCT01301924Phase 2CompletedPrimary

Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis

NCT01790659Phase 3CompletedPrimary

Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama

NCT02979002CompletedPrimary

Accuracy of a Rapid Diagnostic Test for Cutaneous Leishmaniasis in Morocco

Scroll to load more

Research Network

Activity Timeline